

Joint Research Management Office

Research News Bulletin

Issue 106

26 November 2018

The Research News Bulletin is edited by Nick Good ~ nicholas.good@bartshealth.nhs.uk

Need to know

Patient Research Champions	2
Research data sharing plans required	2
Research Ethics Committee experts needed	3
New BH-QMUL research misconduct investigation process in operation	3
QMUL Engagement and Enterprise Awards 2019	3
Excess Treatment Costs guidance	4
Library services open-access funding used up	4
HRA and MHRA joint statement on eConsent	4
Barts Pharmacy new Sponsor Information Pack	4

JRMO news

JRMO staff long service awards	4
New Director of Research Services	5
New JRMO SOPs	5

Local research

First immunotherapy success for triple-negative breast cancer	5
New dental adhesive prevents tooth decay around orthodontic brackets	6
Breast screening lowers risk of breast cancer death by 60%	6

Events

Cancer Stem Cell Symposium 2018	7
EARMA Annual Conference	7
JRMO drop-in sessions	8
RDS London drop-in clinics	8

Training

JRMO GCP training	8
-------------------	---

Research Funding

Grants, fellowships and awards	8
--------------------------------	---

<u>Research Professional funding database access</u>	12
--	----



Need to know

Patient Research Champions

Our Research Engagement and Diffusion team has Trust-approved Patient Research Champions (PRCs) who are ready to support your research team.

PRCs are volunteers, registered through the Trust's Volunteers Service, who have undergone all relevant checks and required Trust training. They have also indicated to the E&D team specific areas that they are interested in, which will be used to match them to research teams.

PRCs could help your research team with the following types of tasks:

- Meet and greet trial participants when they come in for their appointments;
- Promote research in our hospitals and/ or at special events;
- Book study appointments and make reminder calls;
- File, copy or scan study documents;
- Create and maintain databases;
- Put together lab kits; and/or
- Be a member of an advisory group helping our researchers to design and develop studies.

If you would like to take on a volunteer or for more information please contact Olivia Coleman or Neeta Patel at patientsinresearch@bartshealth.nhs.uk or call them on 020 7363 8923.



Research data sharing plans required

The International Committee of Medical Journal Editors (ICMJE) has revised its rules on what information needs to be published in relation to clinical trials that feature in its members' journals.

As of 1 July 2018 manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data-sharing statement. Clinical trials that begin enrolling participants on or after 1 January 2019 must include a data-sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained [in full on its website](#), which includes examples of data-sharing statements that would meet the new requirements. Additionally, if a trial's data-sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript, and updated in the relevant registry record.

These requirements do not yet mandate data-sharing. However, investigators should be aware that editors may take into consideration data-sharing statements when making editorial decisions. Some ICMJE member journals already maintain or may choose to adopt, more stringent requirements for data-sharing.

Sharing clinical trial data is one step in a process articulated by the World Health Organization (WHO) and other professional organisations as the best practice for clinical trials. Those steps include universal prospective registration, public disclosure of results from all clinical trials (including through journal publication), and data-sharing. The momentum is clearly one where the new norm is data-sharing; designed to promote greater understanding and collaboration among funders, ethics committees, journals, researchers, data analysts, participants and others.

For further information on how this will operate in the UK [please see the BMJ website here](#).

Research Ethics Committee experts needed

London's Research Ethics Committees (RECs) are looking at ways to better engage with healthcare professionals who would be keen to join as an expert member to provide advice on such studies.



These RECs review the ethical side of Health and Social Care research applications made through the HRA submission portal. Two of their committees are in need of expert members: The London-Dulwich Research Ethics Committee, which meets monthly at the Weston Education Centre in King's College Hospital, and the London Surrey Borders Ethics Committee, which meets monthly at Skipton House in Elephant and Castle.

Any healthcare professionals who are interested in serving on these committees, or who would be interested in this work in other areas in the future, are asked to contact Will Rowland, REC Assistant at **Research Health Authority**, Ground Floor, Skipton House, 80 London Road, London, SE1 6LH, or by email to william.rowland1@nhs.net

New BH-QMUL research misconduct investigation process in operation

At the beginning of November QMUL's Senate approved the research misconduct procedure proposed by the JRMO.

A joint policy for managing allegations of research misconduct had been agreed by both QMUL and Barts Health in late summer 2017. However, at that time there were outstanding issues around the practical management of such allegations; the Senate had asked to see more detail on how such allegations would be managed.

The Standard Operating Procedure (SOP) that has now been agreed was created by the JRMO in conjunction with the HR departments of both QMUL and Barts Health and in consultation with other stakeholders. The SOP sets out the roles and responsibilities for various parties and describes procedures for:

- (i) Registering a complaint;
- (ii) Undertaking an initial investigation;
- (iii) Running a research misconduct panel; and
- (iv) Managing the outcome.

In allegations where QMUL is the lead organisation, the Academic Secretariat is responsible for oversight of the process, with assistance from the JRMO and others as relevant. In allegations where Barts Health is the lead organisation that role sits with the Chief Medical Officer, again assisted by the JRMO and others as relevant. On the QMUL side, the policy covers all types of research misconduct allegation; it is not restricted to just medical or clinical research.

Both the new procedure and its related policy are available on the JRMO website: Joint Research Management Policy 23 can be found [here](#); SOP 33 can be found [here for medical research](#) and [here for non-medical research](#).

QMUL Engagement and Enterprise Awards 2019

The Engagement and Enterprise Awards recognise outstanding achievement in public engagement, academic innovation, student enterprise and public relations. Nominations for the 2019 awards are now open and will close Monday 10 December.

Awards are made in four categories:

- [Public Engagement](#)
- [Media Relations](#)
- [Academic Innovation](#)
- [Student Enterprise](#)

Individuals can nominate themselves or a colleague. Please follow the above links for more information and to make nominations.

Excess Treatment Costs guidance

The NIHR has published a [flowchart to show how the new Excess Treatment Cost \(ETC\) arrangements will apply to existing studies](#). This guidance includes worked examples for single and multiple arm studies. The Association of Medical Research Charities (AMRC) has also published a [Q&A on ETCs](#) for funders, which includes input from the NIHR as well as the Department of Health and Social Care, NHS England and the Health Research Authority.

The NIHR is continuing to work through its CRNs to ensure that ETCs within public health studies are identified.

Library services open-access funding used up

QMUL is in receipt of a block grant from RCUK/UKRI to help researchers in receipt of Research Council funding to meet open access policy requirements. This fund runs from April to March each year that the funding for 2018-19 has now been fully committed: No further requests for open access support can be considered until next year's award begins in April 2019.

Researchers looking for non-financial assistance, for example checking whether their paper complies with the RCUK's open access policy, can contact Library Services at scholarlycommunications@qmul.ac.uk

HRA and MHRA joint statement on eConsent

The HRA and MHRA have published a joint statement on seeking and documenting consent using electronic methods (eConsent). This sets out the legal and ethical requirements for seeking and documenting consent using electronic methods and is supported and endorsed by the UK health Departments in Northern Ireland, Scotland and Wales. [Further information can be found on the HRA website here.](#)

Barts Pharmacy new Sponsor Information Pack

Barts Health's Pharmacies offer a comprehensive range of services to support researchers and funders involved in clinical trials. Assistance is available from the point of inception through to the final archiving of data.

It has recently launched a new Sponsor Information Pack, setting out what the unit offers and how its services can be accessed, which [is available on the Pharmacy page of the JRMO website.](#)

Information on the JRMO's [Setting up a Study](#) page has also been updated to include a new FAQ ('What if my study involves the use of Barts Health's Pharmacy') that links back to the Pharmacy Support page and the Sponsor Information Pack.

JRMO news

JRMO staff long service awards

Two of the JRMO's key staff received awards for long service at a ceremony at the Great Hall, St Bartholomew's Hospital on 11 November. Barts Health CEO Alwen Williams presented awards to Peng Lim for 30 years' service with the Trust and to Halima Master for 25 years' service.

Peng and Halima, shown here with Alwen Williams, are, together, the JRMO's Financial Accounting Team.



New Director of Research Services

We welcome a new Director of Research Services, Dr Sharon Ellis.



Dr Ellis will lead QMUL's business development and innovations team to maintain and enhance the University's competitive position. Working in partnership with Barts Health NHS Trust, Dr Ellis will also have responsibility for the [JRMO](#) which provides financial, research governance and other support for research at both the University and the Trust.

In her previous position, as Director of International Science and Innovation at the Department for Business, Energy and Industrial Strategy (BEIS), Dr Ellis led on European Policy related to science and innovation programmes, including future relationships with the EU and international relations with other countries.

She was the senior official responsible for BEIS' Global Challenges Research Fund and the Newton Fund, which aims to support research and innovation to address global challenges and improve the wellbeing of developing countries, and had responsibility for policy in relation to

the Meteorological Office, National Physical Laboratory and the UK National Academies.

New JRMO SOPs

Since the last Research News Bulletin the JRMO has released the following new or revised Standard Operating Procedures (SOPs) and associated documents:

- SOP 11b [Barts Health/ QMUL sponsorship of MHRA-regulated trails: Process for JRMO](#)
- SOPs 11a & 11b, associated document 1: [JRMO document submission checklist](#)
- SOP 11b, associated document 13: [Sponsorship email template](#)
- SOP 12a, associated document 1: [JRMO protocol template for interventional studies](#)
- SOP 13a, associated document 1: [JRMO protocol template for research studies](#)
- SOP 28, associated document 2c: [Pharmacy monitoring form](#)
- SOP 28, associated document 5: [Quarterly monitoring report](#)
- SOP 33: [The investigation and resolution of research misconduct allegations](#)
- SOP 38a: [Use of computerised equipment, software and systems in clinical research](#)
- SOP 45: [External documentation including Trial Master Files and files for all external sites and facilities](#)

These and all other current JRMO SOPs are [available to download from the JRMO website](#).

Local research

First immunotherapy success for triple-negative breast cancer

There is new hope for those with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer.

New research at St Bartholomew's Hospital with QMUL has shown that by using a combination of immunotherapy and chemotherapy the body's own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

The research, which is published today in the [New England Journal of Medicine](#) and presented at the European Society for Medical Oncology 2018 Congress in Munich, also showed that the combined treatment reduced the risk of death or cancer progressing by up to 40%.



Triple-negative breast cancer often affects young women, with many people diagnosed in their 40s or 50s. The standard treatment is chemotherapy, which most patients quickly develop resistance to. If the disease spreads to other parts of the body, survival is often only 12 to 15 months.

The new treatment combines standard weekly chemotherapy with the immunotherapy medication atezolizumab which is given once every two weeks. The combination works by chemotherapy 'roughening up' the surface of the cancer, which enables the immune system to better recognise and therefore fight the cancer as a foreign object.

Author of the trial Prof Peter Schmid, Clinical Director of the Breast Cancer Centre at St Bartholomew's Hospital and Professor of Cancer Medicine at QMUL, explained that the results represent a significant step forward. This work changes how triple-negative breast cancer is treated in proving for the first time that immune therapy has a substantial survival benefit.


Based on the results of this trial new treatments are currently under review and will hopefully become available in the NHS in the near future. In the interim, patients at St Bartholomew's Hospital with triple-negative breast cancer are offered immunotherapy within ongoing trials.

New dental adhesive prevents tooth decay around orthodontic brackets

Researchers at QMUL, led by Prof Robert Hill, have produced a new orthodontic bracket bonding adhesive that protects tooth surfaces around brackets from decay.

Nearly 70% of people fitted with orthodontic braces experience what is known as "white spot lesions". The problem areas are around the edges of the retaining brackets where plaque accumulates. Because of the wires and brackets, it is difficult to keep the teeth clean. This results in many patients ending up with straight teeth after orthodontics but with marks that can affect their willingness to smile and reduce their self-confidence. This discolouration can take months or even years to disappear.

The new bioactive bonding adhesive differs from the currently used materials by continuously releasing fluoride, calcium and phosphate to form fluorapatite.




Fluorapatite re-mineralises adjacent tooth surfaces and can help reduce plaque formation around the brace, reducing the risks of decay. This built on previous work to develop [BioMin F toothpaste](#).

The research is published in the journal [Dental Materials](#).

Breast screening lowers risk of breast cancer death by 60%

Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women, led in the UK by QMUL.



The research found that women who chose to participate in an organised breast cancer screening programme had a 60% lower risk of dying from breast cancer within 10 years after diagnosis, and a 47% lower risk of dying from breast cancer within 20 years after diagnosis. The study authors say this benefit occurs because screening detects cancers at an earlier

stage, meaning that those diagnosed can respond better to treatment.

The study was co-authored and funded by the [American Cancer Society](#) and appears in the American Cancer Society's peer-reviewed journal [Cancer](#).

In the UK, mammography screening is offered to all women aged 50-70 through the NHS Breast Screening Programme, with participation rates averaging more than 70% but varying dramatically across the country, with lower rates of screening in poorer, inner-city areas.

Senior author Professor Stephen Duffy from [QMUL's Wolfson Institute of Preventive Medicine](#) said that these results demonstrated the vital role that screening has to play, giving women a much greater benefit from modern treatments.

Events

Cancer Stem Cell Symposium 2018

The annual Cancer Stem Cell Symposium takes place on Wednesday 28 November, 9 am to 6:30 pm, in the Bearsted Lecture Theatre and the Old Library on the Whitechapel campus at Queen Mary University of London.

The meeting provides comprehensive updates on a range of cancer stem cell topics, reports recent research, and provides opportunities during the coffee and lunch breaks, and during the after-meeting reception, to network with colleagues who have active research interests in stem cells and cancer. There is an interesting line up of speakers this year and it should be an informative and stimulating day. I attach a flyer and preliminary programme for this event for your information.

QMUL staff wishing to register should [click here](#).

Non-QMUL staff can register to attend [using this link](#).

EARMA Annual Conference

Registration for the 25th EARMA Annual Conference is now open. You can book your place at the early bird rate until the 25 January 2019 [here](#).

This year's conference has the theme 'Supporting a Sustainable Future for Research' and will take place at the Palazzo dei Congressi in Bologna from 27 to 29 March 2019.

More details about the conference can be found [on the conference website](#).



JRMO drop-in sessions

The JRMO runs monthly research advice drop-in sessions on the second Wednesday of every month. There is no need to book - please just turn up.

We will be happy to assist with any research support topics including:

- Project Set-up
- Research Governance
- Finance
- Costing and contracts
- Patient and public involvement

All sessions take place from 10 am to 12 noon. The next planned dates are 12 December 2018 and 9 January 2019.

[Venue: JRMO meeting room, Lower Ground Floor, QM Innovation Centre, 5 Walden Street, Whitechapel](#)

RDS London drop-in clinics

RDS London holds regular next drop-in clinics for researchers preparing applications to NIHR Applied Health Streams (RfPB, EME, HTA, Programme Grants, Programme Development Grants and Fellowships) or medical charities. Drop-ins take place in East London on the last Friday of the month. RDS London can support researchers at all stages of preparing grant applications. Advice and guidance can be provided on study design, identifying a research team and targeting an appropriate funding stream.

The next East London clinic will be held on Fridays 30 November, 12 – 2 pm. There is no need to book, just turn up on the day: Room G15, Yvonne Carter Building, 58 Turner Street, London, E1 2AD (reception: 020 7882 5882).

[For more information please click here.](#)

Training

JRMO GCP training

It is QMUL and BH policy that all researchers conducting research at our sites must attend appropriate training. It is mandated that all researchers of MHRA regulated trials must complete a GCP course and refresh it every 2 years. The same is advised as the best practice for all other researchers.

To book a place on JRMO run GCP-related training courses please [visit our website.](#)

Core courses available are:

- GCP full course
- GCP refresher
- GCP for Labs
- Good practice for research studies
- Good practice for interventional studies
- Planning and managing your ethical research project

[For more information on dates and instructions on how to book your places please see the JRMO website](#) or email research.governance@qmul.ac.uk

Research funding

NIHR funding deadlines

[Programme Grants for Applied Research - Competition 28](#)

Closing date: 28 November 2018

Applications are invited for Competition 28 of the Programme Grants for Applied Research programme. The deadline for application is 28 November 2018

[Programme Development Grants - Competition 23](#)

Closing date: 28 November 2018

Applications are invited for Competition 23 of the Programme Development Grants programme. The deadline for application is 28 November 2018 at 1 pm.

[18/107 Intervention or expectant management for early-onset fetal growth restriction in twin pregnancy](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1

applications to their commissioned workstream for this primary research topic.

[18/108 Anti-TB drug hepatotoxicity and treatment reintroduction](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/109 Management of partial-thickness rotator cuff tears](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/110 Management of undisplaced intracapsular hip fracture](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic,

[18/117 Adjustable hook-and-loop-fastened compression systems for the treatment of venous leg ulcers](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/118 Timing of stoma closure in neonates](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/119 Nutrient enriched diet for babies with a brain injury](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/120 Identification of older patients likely to require enhanced care on discharge from hospital](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/121 Improving engagement and health and care outcomes for people with co-existing mental health and substance misuse conditions](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/122 Pain management pathways for chronic pancreatitis](#)

Closing date: 5 December 2018

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[Invention for Innovation \(i4i\) Product Development Awards - Call 17](#)

Closing date: 12 December 2018

Applications are invited for the NIHR Invention for Innovation (i4i) Product Development Awards. These awards comprise both early and late stages of R&D including the clinical development of laboratory-validated technologies or interventions.

[Public Health Research Programme Rapid Funding Scheme](#)

Closing date: 31 December 2018

The RFS has been set up to provide the public health research community with an accelerated route to funding for small-scale, short and time-sensitive proposals that demonstrate a need for a rapid commissioning process to be followed.

[Cochrane review gold open access scheme](#)

Closing date: 1 January 2019

Cochrane Review Authors can apply to have their reviews published under Gold open access, meaning that they are instantly and freely open for all users to access on the Cochrane Library from the date of publication.

[18/136 Health Services and Delivery Research Programme: standard researcher-led](#)

Closing date: 10 January 2019

The Health Services and Delivery Research (HS&DR) Programme are accepting stage 1 applications to their researcher-led workstream.

[18/137 Health Services and Delivery Research Programme: researcher-led evidence synthesis](#)

Closing date: 10 January 2019

The Health Services and Delivery Research (HS&DR) Programme is accepting stage 2 evidence synthesis applications to their researcher-led workstream.

[18/132 Health Technology Assessment Programme researcher-led evidence synthesis](#)

Closing date: 16 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their researcher-led workstream.

[18/133 Health Technology Assessment Programme researcher-led primary research](#)

Closing date: 16 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their researcher-led workstream

[18/135 Nebulised saline in patients with COPD](#)

Closing date: 23 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

[18/95 - Rivastigmine for psychotic symptoms associated with Parkinson's disease](#)

Closing date: 23 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:

[18/96 - Hormone therapy for premature ovarian insufficiency](#)

Closing date: 23 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:

[18/97 - Hysteroscopic removal of uterine cavity abnormalities to improve fertility](#)

Closing date: 23 January 2019

The Health Technology Assessment Programme is accepting stage 1

applications to their commissioned workstream for this primary research topic:

[18/98 - Oral nutritional interventions in malnourished frail elderly](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this evidence synthesis topic.

[18/100 - Strategies for the management of chronic constipation in childhood](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this topic:

[18/101 - Interventions for the management of perceptual disorders following stroke](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this topic:

[18/102 - Left ventricular assist devices as destination therapy for advanced heart failure](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this topic:

[18/103 - Recurrent intra-articular corticosteroid injections in osteoarthritis](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:

[18/104 - Prevention of incontinence-associated dermatitis](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:

[18/105 - Non-invasive neurally adjusted ventilator assist for neonates requiring respiratory support](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1

applications to their commissioned workstream for this primary research topic:

[18/134 Active case finding of coeliac disease](#)

Closing date: 30 January 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this evidence synthesis topic.

For further information on these and other grants available from the NIHR please see the NIHR website:

<http://www.nihr.ac.uk/funding-and-support/current-funding-opportunities/>

To subscribe to the NIHR's themed call mailing list please [click here](#).

EU research funding

- **Marie Skłodowska-Curie Innovative Training Networks (ITN). Deadline 15 January 2019 (Budget €470m).** MSCA ITN networks fund joint training and or doctoral programmes via research by partnerships of HEIs, research institutions, businesses, SMEs and other socio-economic actors. 3 strands: European Training Networks (ETN); European Industrial Doctorates (EID); and European Joint Doctorates (EJD). 'Bottom-up' schemes in any area of research. Funding based on EC flat rates for researcher allowances (salary) and research related costs and management/overhead costs. [For more information click here.](#)
- **European Research Council (ERC) Consolidator Grant (CoG). Deadline 7 February 2019 (Budget €602m).** For excellent researchers 7-12 years post PhD (*PhD measured from 1st January 2019*). Funds innovative, ambitious and ground-breaking 'frontier' research in any research area for top researchers, as future leaders in their field. As investigator-driven there is no requirement for partners. 100% funding of eligible costs and 25% overheads, up to €2m per project max. 5 years. [For more information click here.](#)

The above schemes have annual calls only. If you have yet to discuss your plans to apply as either a partner or a co-ordinator with your EU Unit pre-award officer, please contact the team immediately:

Cate Cowton c.cowton@qmul.ac.uk
(SBCS, EECS, Maths, Economics, History, SLLF, Law/CCLS, BCI, Wolfson)

Paul Giuliani p.giuliani@qmul.ac.uk
(SEMS, Physics and Astronomy, School of Business & Management, English & Drama, Geography, Politics, Blizard, Dentistry, WHRI)

There remain many EU H2020 funding opportunities under the (2018-2020) work programmes. [For more information, and to apply, please see the EC Funding and Tender Opportunities Portal](#)

Industrial Strategy Challenge Fund: Digital Innovation Hub Sprint Exemplar Innovation Projects

A £3M funding competition for projects that will inform and shape the design and specification of the Digital Innovation Programme is now live. Between six to eight 'Sprint Exemplar Innovation Projects' are sought from academic, NHS and industry consortia that demonstrate real-world examples of using health data in a trustworthy way to improve health and drive innovation across the UK. The purpose is to establish "confidence in concept" of the Digital Innovation Hub Programme technology solutions and proof of readiness for research that will make game-changing improvements in the health of patients and populations and accelerate innovation in UK life sciences.

This competition is an early step towards the delivery of the Digital Innovation Hub Programme, which aims to create a UK-wide infrastructure to securely and safely connect regional health and care data with biomedical data. It is funded by UK Research and Innovation through the Industrial Strategy Challenge Fund's Data to Early Diagnosis and Precision Medicine Challenge.

For further information about the competition for Sprint Exemplar Innovation

Projects and to apply please visit the [Medical Research Council's website](#).

The closing date for applications is 9 am on 7 December 2018.

To find out more about the Digital Innovation Hub Programme and to sign up to our events, please visit the [Health Data Research UK website here](#).

A-T research proposals

Action for A-T is inviting medical research applications for research into Ataxia Telangiectasia. Applications are invited for high-quality research projects that have the potential to lead to treatments and cures for Ataxia Telangiectasia.

Researchers keen to inquire about submitting a grant application should email us with a brief summary of the research proposed which should include the aim of the work, potential clinical application and [how it fits the remit of the charity](#).

If the proposed research is within Action for A-T's remit, researchers will be invited to submit a full research grant application and provided with further information.

Applications are encouraged for project grants of up to 3 years in duration for a maximum award of £100,000 (to cover a research post, consumables and essential equipment). The deadline for submission of full applications is Monday 3 December 2018. For more information please contact the charity please at info@actionforAT.org

BMA Foundation for Medical Research

Online applications for the 2019 grants will open on 1 January 2019 and close on 1 March 2019. Applications must be submitted via the BMA Foundation for Medical Research online application system.

Grant categories for 2019:

- Dawkins & Strutt grant for research into gastroenterology
- Doris Hillier grant for research into rheumatism and arthritis
- H C Roscoe grant for research into viral diseases of the respiratory system
- Helen H Lawson grant for paediatric research
- J Moulton grant to assist research into mental health through clinical trials
- The James Trust grant for research into asthma
- Josephine Lansdell grant for research into heart disease
- Kathleen Harper grant for research into antimicrobials
- Margaret Temple grant for research into schizophrenia
- Scholarship grant to promote research into the mental health of medical students
- TP Gunton grant for research into public health relating to cancer
- Vera Down grant for research into neurological disorders

For further information [see the BMA website here](#).

Research professional

Research Professional (formerly Research Research) now offers an easy to use sign up: <http://www.researchprofessional.com/>

Funding information: [Further funding information can be found on the Research Professional website – to access click here \(account and password required\)](#).